EOLS · Evolus, Inc. · Executive Compensation

$7.84 -0.07 (-0.88%) At close · Sep 11

Russell 2000 member Rebalance outlook locked

Market Cap

$517.84M

66.05M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	President and Chief Executive Officer	$775,000	—	$3,886,569	$1,296,697	$429,000	$24,948	$6,412,214
Tatjana Mitchell	Chief Financial Officer	$154,224	$100,000	$1,420,509	$1,368,036	$111,200	$9,303	$3,163,272
Sandra Beaver	Former Chief Financial Officer	$231,904	—	$968,607	$484,746	—	$14,641	$1,699,898
Rui Avelar	Chief Medical Officer and Head of Research and Development	$545,400	—	$645,756	$323,161	$166,600	$18,167	$1,699,084
Tomoko Yamagishi-Dressler	Former Chief Marketing Officer	$285,163	—	$484,317	$242,378	$73,425	$502,825	$1,588,108

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	President and Chief Executive Officer	$743,750	—	$3,549,882	$1,777,038	$900,000	$28,207	$6,998,877
Rui Avelar	Chief Medical Officer and Head of Research and Development	$515,725	—	$1,609,966	$463,571	$280,500	$14,851	$2,884,613
Sandra Beaver	Chief Financial Officer	$477,625	—	$694,544	$463,571	$260,800	$14,783	$1,911,323
Tomoko Yamagishi-Dressler	Chief Marketing Officer	$429,525	—	$486,182	$324,501	$233,100	$14,749	$1,488,057
Tatjana Mitchell	Chief Financial Officer	—	—	—	—	—	—	—

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	President and Chief Executive Officer	$687,500	—	$7,417,415	$2,075,862	$1,017,800	$41,870	$11,240,447
Rui Avelar	Chief Medical Officer and Head of Research and Development	$487,750	—	$1,414,034	$691,957	$320,610	$14,827	$2,929,178
Sandra Beaver	Chief Financial Officer	$437,500	—	$1,027,634	$691,957	$287,890	$14,756	$2,459,737
Tomoko Yamagishi-Dressler	Chief Marketing Officer	$151,302	$35,000	$595,565	$595,563	$271,530	$43,161	$1,692,121
Tatjana Mitchell	Chief Financial Officer	—	—	—	—	—	—	—

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	President and Chief Executive Officer	$596,875	—	$1,170,002	$1,161,522	$643,200	$27,991	$3,599,590
Sandra Beaver	Chief Financial Officer	$136,818	$100,000	$330,174	$1,125,002	$135,100	$313	$1,827,407
Lauren Silvernail	Former Chief Financial Officer and Executive Vice President, Corporate Development	$184,167	—	$582,300	$290,381	—	$375,650	$1,432,498
Rui Avelar	Chief Medical Officer and Head of Research and Development	$469,000	—	$292,498	$290,381	$202,400	$10,633	$1,264,912
Tomoko Yamagishi-Dressler	Chief Marketing Officer	—	—	—	—	—	—	—

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	President and Chief Executive Officer	$571,875	—	$2,300,335	—	$632,500	$25,168	$3,529,878
Rui Avelar	Chief Medical Officer and Head of Research and Development	$445,000	—	$582,300	—	$207,390	$7,687	$1,242,377
Lauren Silvernail	Former Chief Financial Officer and Executive Vice President, Corporate Development	$439,875	—	$582,300	—	$176,800	$13,212	$1,212,187
Sandra Beaver	Chief Financial Officer	—	—	—	—	—	—	—

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	President and Chief Executive Officer	$527,083	—	$1,232,293	$815,869	$720,500	$7,744	$3,303,489
Michael Jafar	Former Chief Commercial Officer	$342,292	—	$573,360	$411,994	$226,475	$2,588	$1,556,709
Lauren Silvernail	Chief Financial Officer and Executive Vice President, Corporate Development	$407,292	—	$423,340	$258,714	$222,700	$3,820	$1,315,866
Rui Avelar	Chief Medical Officer and Head of Research and Development	$403,333	—	$423,340	$258,714	$222,576	$5,943	$1,313,906

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	President and Chief Executive Officer	$550,000	—	—	$1,169,813	$555,500	$3,500	$2,278,813
Rui Avelar	Chief Medical Officer and Head of Research and Development	$400,000	—	—	$561,510	$861,600	$13,500	$1,836,610
Lauren Silvernail	Chief Financial Officer and Executive Vice President, Corporate Development	$425,000	—	—	$421,133	$171,700	$3,500	$1,021,333
Michael Jafar	Former Chief Commercial Officer	$345,000	—	—	$421,133	$139,380	—	$905,513

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	President and Chief Executive Officer	$361,731	$75,000	—	$4,995,803	$361,644	—	$5,794,178
Lauren Silvernail	Chief Financial Officer and Executive Vice President, Corporate Development	$253,365	—	$673,200	$2,604,260	$101,068	$25,000	$3,656,893
Rui Avelar	Chief Medical Officer and Head of Research and Development	$367,885	—	$1,202,688	$1,425,752	$160,000	—	$3,156,325

Executive changes

Person	Role	Change	Effective	Filed
Vikram Malik	Class II director	Appointed	2026-03-13	2026-03-13
Vikram Malik	Class III director	Resigned	2026-03-13	2026-03-13
Tatjana Mitchell	Chief Financial Officer	Appointed	2025-09-08	2025-09-08
David Moatazedi	Principal Financial Officer	Appointed	2025-08-01	2025-08-05
Albert White III	Class I Directors	Appointed	2025-06-05	2025-06-06
David Gill	Class I Directors	Appointed	2025-06-05	2025-06-06
Sandra Beaver	Chief Financial Officer	Resigned	2025-06-13	2025-05-27

Key facts CIK 1570562 CUSIP 30052C107 13F (30d) 83 filings 83 filers Visit website Investor relations